Studies on the role of brain monoamines in the anticonvulsant action of diphenylhydantoin and nialamide-induced potentiation of diphenylhydantoin in albino rats

  • S. K. Bhattacharya
  • P. K. S. P. Reddy
  • P. K. Das


The role of brain monoamines in the anticonvulsant action of diphenylhydantoin, is controversial. Several workers (Rudzik and Mennear, 1965; Gray and Rauh, 1967; Rudzik and Johnson, 1970; Meyer and Frey, 1973) have provided evidence for an adrenergic mediation, while others (Bonnycastle, Paasonen and Giarman, 1956; Bonnycastle, Giarman and Paasonen, 1957; Anderson, Markowitz and Bonnycastle, 1962) have implicated 5-hydroxytryptamine (5-HT) as the mediator. Prockop, Shore and Brodie (1959) have claimed, however, that the anticonvulsant effect of diphenylhydantoin is unrelated to brain monoamines. Similarly, the role of brain monoamines in electroshock seizure threshold, is equally controversial (for literature see Mantegazzini, 1966; Kilian and Frey, 1973).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andén, N. E., Rubenson, A., Fuze, K. and Hökfelt, T. (1967). ‘Evidence for dopamine receptor stimulation by apomorphine’, J. Pharm. Pharmac., 19, 627–629CrossRefGoogle Scholar
  2. Anderson, F. G., Markowitz, S. D. and Bonnycastle, D. D. (1962). ‘Brain 5-hydroxytryptamine and anticonvulsant activity’, J. Pharmac. exp. Ther., 136, 179–182Google Scholar
  3. Angeletti, P. U. (1971). ‘Chemical sympathectomy in new born animals’, Neuropharmacology, 10, 55–59PubMedCrossRefGoogle Scholar
  4. Azzaro, A. J., Wenger, G. R., Craig, C. R. and Stitzel, R. E. (1972). ‘Reserpine induced alterations in brain amines and their relationship to changes in the incidence of minimal electroshock seizures in mice’, J. Pharmac. exp. Ther., 180, 558–568Google Scholar
  5. Bonnycastle, D. D., Paasonen, M. K. and Giarman, N. J. (1956). ‘Diphenylhydantoin and brain levels of 5-HT’, Nature, 178, 990–991PubMedCrossRefGoogle Scholar
  6. Bonnycastle, D. D., Giarman, N. J. and Paasonen, M. K. (1957). ‘Anticonvulsant compounds and 5-HT in rat brain’, Br. J. Pharmac., 12, 228–231Google Scholar
  7. Carlsson, A., Rosengren, E., Bertler, A. and Lindqvist, M. (1966). ‘Biochemical and histochemical studies on the effects of imipramine like drugs and (+)-amphetamine on central and peripheral catecholamine neurones’, Acta physiol. scand., 67, 481–497PubMedCrossRefGoogle Scholar
  8. Carlsson, A., Lindqvist, M., Fuxe, K. and Hökfelt, T. (1966). ‘Histochemical and biochemical effects of diethyldithiocarbamate on tissue catecholamines’, J. Pharm. Pharmac., 18, 60–62CrossRefGoogle Scholar
  9. Chen, G. and Bohner, B. (1959). ‘A comparison of the antireserpine effects of certain centrally acting agents’, Fedn Proc. Fedn Am. Socs exp. Biol., 18, 376Google Scholar
  10. Chen, G., Ensor, C. R. and Bohner, B. A. (1954). ‘A facilitative action of reserpine on the central nervous system’, Proc. Soc. exp. Biol. Med., 86, 507–510PubMedCrossRefGoogle Scholar
  11. Ernst, A. M. (1967). ‘Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats’, Psychopharmacologia, 10, 316–323PubMedCrossRefGoogle Scholar
  12. Ernst, A. M. and Smelik, P. G. (1966). ‘Site of action of dopamine and apomorphine on gnawing compulsion behaviour in rats’, Experentia, 22, 837–838CrossRefGoogle Scholar
  13. Fog, R. (1972). ‘On stereotypy and catalepsy: Studies on the effect of amphetamines and neuroleptics in rats’, Acta neurol. scand., 48, 1–66 Suppl. 50CrossRefGoogle Scholar
  14. Fog, R. Randrup, A. and Pakkenberg, H. (1968). ‘Neuroleptic action of quaternary chlorpromazine and related drugs injected into various brain areas in rats’, Psychopharmacologia, 12, 428–432PubMedCrossRefGoogle Scholar
  15. Fog, R., Randrup, A. and Pakkenberg, H. (1971). ‘Intrastriatal injection of quaternary butyrophenones and oxypertine—neuroleptic effect in rats’, Psychopharmacologia, 19, 224–230PubMedCrossRefGoogle Scholar
  16. Frey, H.-H. (1970). ‘p-Chloroamphetamine-similarities and dissimilarities to amphetamine; in Amphetamine and Related Compounds (Costa, E. and Garattini, S., Eds), 343–347, Raven Press, New YorkGoogle Scholar
  17. Fuller, R. W., and Walters, C. P. (1965). ‘Inhibition of monoamine oxidase action on kynuramine by substrate amines and ac-methylamines’, Biochem. Pharmac., 14, 159–163CrossRefGoogle Scholar
  18. Gray, W. D. and Rauh, C. E. (1967). ‘The anticonvulsant action of inhibitors of carbonic anhydrase: relation to endogenous amines in brain’, J. Pharmac. exp. Ther., 155, 127–134Google Scholar
  19. Gray, W. D. and Rauh, C. E. (1971). ‘The relation between monoamines in the brain and anticonvulsant effect of inhibitors of carbonic anhydrase’, J. Pharmac. exp. Ther., 177, 206–218Google Scholar
  20. Glowinski, J. and Axelrod, J. (1964). ‘Inhibition of uptake of tritiated noradrenaline in the intact rat brain by imipramine and structurally related compounds’, Nature, 204, 1318–1319PubMedCrossRefGoogle Scholar
  21. Hornykiewicz, O. (1971). ‘Dopamine: its physiology, pharmacology and pathological neurochemistry’, in Biogenic Amines and Biological Membranes in Drug Therapy, Medicinal Research Series, Vol. 5, Part B, (Biel, J. H. and Abood, L. G., Eds.), 173–258, Marcel Dekker, New YorkGoogle Scholar
  22. Johnson, G. A., Kim, E. G. and Boukma, S. J. (1968). ‘Mechanism of norepinephrine depletion by 5-hydroxytryptophan’, Proc. Soc. exp. Ther., 128, 509–512CrossRefGoogle Scholar
  23. Kaergaard Nielsen, C., Magnussen, M. P., Kampmann, E. and Frey, H.-H. (1967). ‘Pharmacological properties of racemic and optically active p-chloroamphetamine’, Archs int. Pharmacodyn. Thir., 170, 428–443Google Scholar
  24. Kerkut, G. A., Sedden, C. B. and Walker, R. J. (1966). ‘The effect of DOPA, a-methylDOPA and reserpine on the dopamine content of the brain of the snail, Helix aspersa’, Comp. Biochem. Physiol., 18, 921–930PubMedCrossRefGoogle Scholar
  25. Kilian, M. and Frey, H.-H., (1973). ‘Central monoamines and convulsive thresholds in mice and rats’, Neuropharmacology, 12, 681–692PubMedCrossRefGoogle Scholar
  26. Kleinrok, Z., Zebrowska, I. and Wielosz, M. (1970). ‘Some central effects of diethyldithiocarbamate administered intraventricularly in rats’, Neuropharmacology, 9, 451–455PubMedCrossRefGoogle Scholar
  27. Koe, B. K. and Weisman, A. (1966). ‘p-Chlorophenylalanine, a specific depletor of brain serotonin’, J. Pharmac. exp. Ther., 154, 499–516Google Scholar
  28. Mantegazzini, P. (1966). ‘Pharmacological actions of indolealkylamines and precursor aminoacids in central nervous system’, in Handbook of Experimental Pharmacology, Vol. 16, (Erspamer, V., Ed.), 425–470, Springer-Verlag, New YorkGoogle Scholar
  29. McGeer, P. L., McGeer, E. G. and Wada, J. A. (1963). ‘Central aromatic amine levels and behavior. II. Serotonin and catecholamine levels in various cat brain, areas following administration of psychoactive drugs or amine precursors’, Archs Neurol., 9, 81–89CrossRefGoogle Scholar
  30. McKenzie, G. M. and Soroko, F. E. (1972). ‘The effects of apomorphine, (+)-amphetamine and L-DOPA in maximal electroshock convulsions—a comparitive study in the rat and mouse’, J. Pharm. Pharmac., 24, 696–701CrossRefGoogle Scholar
  31. Meyer, H. and Frey, H.-H., (1973). ‘Dependence of anticonvulsant drug action on central monoamines’, Neuropharmacology, 12, 939–947PubMedCrossRefGoogle Scholar
  32. P’an, S. Y., Funderburk, W. H. and Finger, K. F. (1961). ‘The anticonvulsant effect of nialamide and diphenylhydantoin’, Fedn Proc. Fedn Am. Socs exp. Biol., 20, 323Google Scholar
  33. Piette, Y., Delaunois, A. L., De Schaepdryver, A. F. and Heymans, C. (1963). ‘Imipramine and electroshock threshold’, Archs int. Pharmacodyn Thér., 144, 293–297Google Scholar
  34. Prockop, D. J., Shore, P. A. and Brodie, B. B. (1959). ‘Anticonvulsant properties of monoamine oxidase inhibitors’, Ann. N. Y. Acad. Sci., 80, 643–650PubMedCrossRefGoogle Scholar
  35. Rowe, R. P., Bloom, B. M., P’an, S. W. and Finger, K. F. (1959). ‘The pharmacologic characterisation of the antidepressant nialamide’, Fedn Proc. Fedn Am. Socs. exp. Biol., 18, 376Google Scholar
  36. Rudzik, A. D. and Mennear, J. H. (1965). ‘The mechanism of action of anticonvulsants 1. Diphenylhydantoin’, Life Sci., 4, 2373–2382PubMedCrossRefGoogle Scholar
  37. Rudzik, A. D. and Johnson, G. A. (1970). ‘Effect of amphetamine and amphetamine analogues on convulsive thresholds’, in Amphetamines and Related Compounds (Costa, E. and Garattini, S., Eds.), 715–728, Raven Press, New YorkGoogle Scholar
  38. Sanders-Bush, E., Bushing, J. A. and Sulser, F. (1972). ‘p-Chloroamphetamine inhibition of cerebral tryptophan hydroxylase’, Biochem. Pharmac., 21, 1501–1510CrossRefGoogle Scholar
  39. Sanders-Bush, E. and Sulser, F. (1970). ‘Biochemical considerations on the mode of action of p-chloroamphetamine’, in Amphetamines and Related Compounds (Costa, E. and Garattini, S., Eds.), 349–355, Raven Press, New YorkGoogle Scholar
  40. Schlesinger, K., Boggan, W. and Grick, B. (1968). ‘Pharmacogenetic correlates of pentylenetetrazole and electroshock seizure threshold in mice’, Psychopharmacologia, 13, 181–188PubMedCrossRefGoogle Scholar
  41. Sourkes, T. L. (1965). ‘Action of a-methyldopa in the brain’, Br. Med. Bull., 21, 66–69Google Scholar
  42. Spector, S., Sjoerdsma, A. and Udenfriend, S. (1965). ‘Blockade of endogenous norepinephrine synthesis by α-methyltyrosine, an inhibitor of tyrosine hydroxylase’, J. Pharmac. exp. Ther., 147, 86–95Google Scholar
  43. Ungerstedt, U. (1971). ‘Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigrostriatal dopamine system’, Acta. physiol. stand., Suppl., 369, 69–91CrossRefGoogle Scholar
  44. Uretsky, N. J. and Iversen, L. L. (1969). ‘Effects of 6-hydroxydopamine on noradrenaline containing neurones in the rat brain’, Nature, 221, 557–560PubMedCrossRefGoogle Scholar
  45. Uretsky, N. J. and Iversen, L. L. (1970). ‘Effect of 6-hydroxydopamine on catecholamine containing neurones in the rat brain’, J. Neurochem., 17, 369–378CrossRefGoogle Scholar
  46. Van Rossum, J. M. (1966). ‘The significance of dopamine receptor blockade for mechanism of action of neuroleptic drugs’, Archs int. Pharmacodyn. Thér., 160, 492–494Google Scholar
  47. Weber, L. J. (1966). ‘Drug interactions between disulfiram and a-methylDOPA and related agents in reserpine pretreated rats’, Proc. Soc. exp. Biol. Med. 123, 349–352PubMedCrossRefGoogle Scholar
  48. Wenger, G. R., Stitzel, R. E. and Craig, C. R. (1973). ‘Brain monoamines and minimal electroshock seizure threshold in mice’, Neuropharmacology, 12, 693–703PubMedCrossRefGoogle Scholar
  49. Yen, H. C. Y., Silverman, A. J., and Salvatore, A. (1960). ‘Iproniazid reinforcement of anticonvulsants’, Fedn Proc. Fedn Am. Socs exp. Biol., 19, 278Google Scholar

Copyright information

© The Contributors 1976

Authors and Affiliations

  • S. K. Bhattacharya
    • 1
  • P. K. S. P. Reddy
    • 1
  • P. K. Das
    • 1
  1. 1.Department of Pharmacology, Institute of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations